Yılmaz Karapınar D.Karadaş N.Siviş Z.Ö.Balkan C.Kavaklı K.Aydınok Y.2019-10-262019-10-2620151300-7777https://doi.org/10.4274/tjh.2014.0250https://hdl.handle.net/11454/17134Experiences with new multikinase inhibitors are limited, especially in children. In this report we summarize our experience with 2 patients with relapsed acute myeloblastic leukemia (AML), one with FMS-like tyrosine kinase- 3-internal tandem duplication mutation and the other with a single base mutation (D835Y). Both patients received sorafenib, one for 19 days and the other for 42 days, with clofarabine-including chemotherapy. One additionally received sunitinib for a total of 20 days. Both patients developed severe pancytopenia, hypertension, life-threatening bleedings from the gastrointestinal system, and, finally, intrapulmonary hemorrhage. Although both reached severe aplasia of the bone marrow without blastic infiltration, death occurred with neutropenic sepsis. © 2015, Turkish Society of Hematology. All rights reserved.en10.4274/tjh.2014.0250info:eu-repo/semantics/openAccessAcute myeloblastic leukemiaChildrenD835Y mutationFLT3SorafenibSunitinibArticle32326326625912283Q3